Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma

Journal of Histochemistry and Cytochemistry

Volumn 50, Issue 12, 2002, Pages 1693-1696

  Selvarajan, Sathiyamoorthy ^a   Bay, Boon Huat ^a   Choo, Andrew ^a   Chuah, Khoon Leong ^a   Sivaswaren, Christina Rudduck ^a   Tien, Sim Leng ^a   Wong, Chow Yin ^a   Tan, Puay Hoon ^a  

^a NONE

Author keywords

Breast cancer; FISH; Fixation; HER2 neu; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL PROCESSING; STANDARDIZATION; TISSUE FIXATION;

EID: 0036939632     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1177/002215540205001215     Document Type: Article

References (12)

1. Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X (2000) Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 13:1238-1243
2. Ellis IO, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, Gusterson B, et al. (2000) Recommendations for HER2 testing in the UK. J Clin Pathol 53:890-892
3. Goelz SE, Hamilton SR, Vogelstein B (1985) Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 130:118-126
4. Gozzetti A, Le Beau MM (2000) Fluorescence in situ hybridization: uses and limitations. Semin Hematol 37:320-333
5. Hoang MP, Sahin AA, Ordonez NG, Sneige N (2000) HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113:852-859
6. Pauletti G, Slamon DJ (1999) Interphase cytogenetics of the HER2/neu oncogene in breast cancer. In Andreeff M, Pinkel D, eds. Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications. New York, Wiley-Liss, 153-171
7. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE (2002) HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148-154
8. Ridolfi RL, Jamehdor MR, Arber JM (2000) HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13:866-873
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic cancer that overexpresses HER2. N Engl J Med 344:788-792
10. Thompson CT, LeBoit PE, Nederlof PM, Gray JW (1994) Thick-section fluorescence in situ hybridization on formalin-fixed, paraffin-embedded archival tissue provides a histogenetic profile. Am J Pathol 144:237-243
11. Vang R, Cooley LD, Harrison WR, Reese T, Abrams J (2000) Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma. Am J Clin Pathol 113:669-674
12. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R (2000) Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 53:374-381